MedTrace Logo

Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors

NCT04980690 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2023-03-10

No results posted yet for this study

Summary

This is a phase I/IIa study to evaluate the safety, tolerability and efficacy of IBC0966 for the treatment of subjects with advanced malignant tumors.

Conditions

  • Advanced Malignant Tumors

Interventions

BIOLOGICAL

IBC0966

IBC0966 is an investigational product.

Sponsors & Collaborators

  • SUNHO（China）BioPharmaceutical CO., Ltd.

    lead INDUSTRY

Principal Investigators

  • Qingyuan Zhang · The Affiliated Tumor Hospital of Harbin Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-31
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04980690 on ClinicalTrials.gov